API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. ST /
  3. CANTA.ST

Cantargia AB (CANTA ST) stock market data APIs

kr2.299 0.44(23.7%) as of November 21, 2024
Price chart is built with Anychart

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.

Cantargia AB Financial Data Overview

2.037
2.299
-
2.098
2.2
1.802-5.2
352 M
184 M
0
-0.2288
1.742
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CANTA',
Type: 'Common Stock',
Name: 'Cantargia AB',
Exchange: 'ST',
CurrencyCode: 'SEK',
CurrencyName: 'Swedish krone',
CurrencySymbol: 'kr',
CountryName: 'Sweden',
CountryISO: 'SE',
OpenFigi: NULL,
ISIN: 'SE0006371126',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Cantargia AB Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -231 820 000
  • Earnings Per Share -1.3
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Cantargia AB Earnings via APIs

  • Latest Release 2024-11-15
  • EPS/Forecast NaN

Get Cantargia AB End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Cantargia AB latest news via APIs

Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead a...

Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been selecte...
  • AACR
  • ABSTRACT NUMBER
  • CANCER
  • CANTARGIA AB
  • CHEMOTHERAPY
  • CLINICAL EFFICACY
  • LUNG METASTASES
  • METASTATIC CANCER
  • NASDAQ STOCKHOLM
  • PANCREATIC CANCER
  • PRECLINICAL RESULTS
  • TUMOR MICROENVIRONMENT
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com